Design, Synthesis, and Biological Activity of 4-[(4-Cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as Potent and Selective Farnesyltransferase Inhibitors
- 1 January 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (3) , 612-626
- https://doi.org/10.1021/jm030434f
Abstract
A novel series of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles have been synthesized as selective farnesyltransferase inhibitors using structure-based design. X-ray cocrystal structures of compound 20-FTase-HFP and A313326-FTase-HFP confirmed our initial design. The decreased interaction between the aryl groups and Ser 48 in GGTase-I binding site could be one possible reason to explain the improved selectivity for this new series of FTase inhibitors. Medicinal chemistry efforts led to the discovery of compound 64 with potent cellular activity (EC(50) = 3.5 nM) and outstanding pharmacokinetic profiles in dog (96% bioavailable, 18.4 h oral t(1/2), and 0.19 L/(h x kg) plasma clearance).Keywords
This publication has 11 references indexed in Scilit:
- Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailabilityBioorganic & Medicinal Chemistry Letters, 2003
- Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issuesExpert Opinion on Investigational Drugs, 2000
- Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the MicrotubulesJournal of Biological Chemistry, 2000
- Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogueEuropean Journal Of Cancer, 2000
- Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic DevelopmentJournal of Clinical Oncology, 1999
- Discovery of a Series of Cyclohexylethylamine-Containing Protein Farnesyltransferase Inhibitors Exhibiting Potent Cellular ActivityJournal of Medicinal Chemistry, 1999
- Second-Generation Peptidomimetic Inhibitors of Protein Farnesyltransferase Demonstrating Improved Cellular Potency and Significant in Vivo EfficacyJournal of Medicinal Chemistry, 1999
- Potent and Selective Non-Cysteine-Containing Inhibitors of Protein FarnesyltransferaseJournal of Medicinal Chemistry, 1998
- Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic miceNature Medicine, 1995
- ras GENESAnnual Review of Biochemistry, 1987